Diagnostic Strategy for Suspected Pulmonary Embolism Based on 4PEPS

Last updated: September 15, 2025
Sponsor: University Hospital, Angers
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Pulmonary Embolism

Cardiovascular Disease

Deep Vein Thrombosis

Treatment

4PEPS strategy

Clinical Study ID

NCT06015529
36553108
  • Ages > 18
  • All Genders

Study Summary

The increased use of diagnostic imaging and especially computed tomography pulmonary angiography in patients suspected of pulmonary embolism (PE) is an important point of concerns.

The goal of this pragmatic cluster-randomized trial is to compare the diagnostic strategy based on the four-level pulmonary embolism probability score (4PEPS) and current practices.

The main questions it aims to answer is: "Does the diagnostic strategy based on 4PEPS significantly reduce the use of thoracic imaging without increasing the risk of serious adverse events as compared to current diagnostic practices?" Patients suspected of having PE in the participating emergency departments will be included and followed for 90 days. In ten centers, the emergency physicians will apply the 4PEPS strategy and in ten other centers, the emergency physicians will be free to do as they see fit. Researchers will compare the two groups of patients to see if the rate of diagnostic thoracic imaging tests and the rate of adverse events related to diagnostic strategies will differ.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Admission to an emergency department participating in the study.

  • Suspected PE due to thoracic symptoms (dyspnea, chest pain, or hemoptysis) and/orsyncope without any other obvious explanation after clinical examination andpossible additional first-line tests (ECG, chest X-ray, or routine lab work-up).

Exclusion

Exclusion Criteria:

  • Age < 18 years.

  • Known result of a specific diagnostic imaging examination for PE (thoracic CTangiography, pulmonary scintigraphy, or venous ultrasound of the lower limbs).

  • Hemodynamic instability (systolic blood pressure < 90 mmHg or more than 40 mmHglower than usual for more than 15 min).

  • Curative dose of anticoagulant in place for more than two days prior to inclusion.

  • Pregnant or parturient patient.

  • Patient in detention by judicial or administrative decision.

  • Patient undergoing compulsory psychiatric treatment.

  • Patient placed under a legal protection measure.

  • Patient who objects to participating in the research (preliminary phase) or isunable to give free and informed consent (active phase).

Study Design

Total Participants: 2951
Treatment Group(s): 1
Primary Treatment: 4PEPS strategy
Phase:
Study Start date:
November 29, 2023
Estimated Completion Date:
September 30, 2025

Study Description

Several strategies have been devised to safely limit the use of thoracic imaging in patients suspected of pulmonary embolism (PE). However, they are based on different rules for clinical probability (CP) assessment, rendering their combination difficult. The four-level pulmonary embolism probability score (4PEPS) allows the combination of all other strategies using a single CP assessment. Methods and analysis: SPEED&PEPS is a pragmatic cluster-randomized trial. After a preliminary period aimed to assess the possibility of inclusions and current practices in 23 Emergency Departments (ED), 20 EDs will be selected to participate to the active phase and randomization. Half of the centers will be allocated to the control group where physicians will be free to do as they see fit but they will be given the recommendation to apply a validated strategy. Half of the centers will be allocated to the interventional group where the physicians will be given the recommendation to apply the 4PEPS strategy. Patients with suspected PE will be included and followed for 90 days (anticipated number of patients to be included: 2560, 1280 in each arm). The primary objective will be to demonstrate that the application of the 4PEPS strategy by emergency physicians, in comparison to current practices, (i) does not increase the risk of serious events related to diagnostic strategies and (ii) significantly reduces the use of thoracic imaging. If successful, the SPEED&PEPS trial will have an important impact for patients suspected of PE limiting their irradiation and for public health in substantial savings in terms of the direct cost of diagnostic investigations and the indirect cost of hospitalizations due to waiting times or delayed harmful effects. Funding: This work is funded by a French Public Health grant (PREPS-N 2019). The funding source plays no role in the study design, data collection, analysis, interpretation or the writing of the manuscript.

Connect with a study center

  • Cliniques Bruxelles

    Brussels 2800866,
    Belgium

    Site Not Available

  • Cliniques Bruxelles

    Bruxelles,
    Belgium

    Site Not Available

  • CHU Liège

    Liège,
    Belgium

    Site Not Available

  • CHU Liège

    Liège 2792413,
    Belgium

    Site Not Available

  • CH Agen

    Agen,
    France

    Site Not Available

  • CH Agen

    Agen 3038634,
    France

    Site Not Available

  • CHU Angers

    Angers, 49000
    France

    Site Not Available

  • CHU Angers

    Angers 3037656, 49000
    France

    Site Not Available

  • CH Argenteuil

    Argenteuil,
    France

    Site Not Available

  • CH Argenteuil

    Argenteuil 3037044,
    France

    Site Not Available

  • CH Arpajon

    Arpajon,
    France

    Site Not Available

  • CH Arpajon

    Arpajon 3036823,
    France

    Site Not Available

  • AP HP Clamart

    Clamart,
    France

    Site Not Available

  • AP HP Clamart

    Clamart 3024783,
    France

    Site Not Available

  • CHU Clermont Ferrand

    Clermont-Ferrand,
    France

    Site Not Available

  • CHU Clermont Ferrand

    Clermont-Ferrand 3024635,
    France

    Site Not Available

  • CHU Grenoble

    Grenoble,
    France

    Site Not Available

  • CHU Grenoble

    Grenoble 3014728,
    France

    Site Not Available

  • CH La Rochelle

    La Rochelle,
    France

    Site Not Available

  • CH La Rochelle

    La Rochelle 3006787,
    France

    Site Not Available

  • CH Versailles

    Le Chesnay,
    France

    Site Not Available

  • CH Versailles

    Le Chesnay 3004630,
    France

    Site Not Available

  • CHU Limoges

    Limoges,
    France

    Site Not Available

  • CHU Limoges

    Limoges 2998286,
    France

    Site Not Available

  • CHU Lyon

    Lyon,
    France

    Site Not Available

  • CHU Lyon

    Lyon 2996944,
    France

    Site Not Available

  • CHR Metz Thionville

    Metz,
    France

    Site Not Available

  • CHR Metz Thionville

    Metz 2994160,
    France

    Site Not Available

  • CHU Nantes

    Nantes,
    France

    Site Not Available

  • CHU Nantes

    Nantes 2990969,
    France

    Site Not Available

  • CHU Nice

    Nice,
    France

    Site Not Available

  • CHU Nice

    Nice 2990440,
    France

    Site Not Available

  • GH Paris

    Paris,
    France

    Site Not Available

  • GH Paris

    Paris 2988507,
    France

    Site Not Available

  • CHU Poitiers

    Poitiers,
    France

    Site Not Available

  • CHU Poitiers

    Poitiers 2986495,
    France

    Site Not Available

  • CH Rochefort

    Rochefort,
    France

    Site Not Available

  • CH Rochefort

    Rochefort 2983276,
    France

    Site Not Available

  • CHU Rouen

    Rouen,
    France

    Site Not Available

  • CHU Rouen

    Rouen 2982652,
    France

    Site Not Available

  • CHU Toulouse

    Toulouse,
    France

    Site Not Available

  • CHU Toulouse

    Toulouse 2972315,
    France

    Site Not Available

  • CHU Tours

    Tours,
    France

    Site Not Available

  • CHU Tours

    Tours 2972191,
    France

    Site Not Available

  • CH Troyes

    Troyes,
    France

    Site Not Available

  • CH Troyes

    Troyes 2971549,
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.